Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jenscare Scientific Co. Ltd. Class H ( (HK:9877) ) has provided an update.
Jenscare Scientific Co., Ltd. forecast that its group revenue for the year ended 31 December 2025, its first full year of commercialization, will reach approximately RMB90 million to RMB92 million, with additional other income and gains of RMB15 million to RMB18 million, bringing total revenue and gains to about RMB105 million to RMB110 million. The revenue performance is driven mainly by strong initial uptake of its Ken-Valve transcatheter aortic valve replacement system in treating aortic regurgitation and mixed aortic valve disease across different hospital tiers in China, alongside paid clinical implantations of multiple structural heart interventional products overseas that have gained recognition from international experts; the company plans to further expand its product portfolio, deepen its international strategic footprint, and enhance operational efficiency in 2026 to support sustainable growth, while cautioning that the disclosed figures are preliminary and unaudited.
More about Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. is a China-based medical device company focused on structural heart disease, specializing in transcatheter interventional products such as its Ken-Valve transcatheter aortic valve replacement system. The company targets multi-tier medical institutions in China and is expanding the clinical application of its portfolio through paid implantations and collaborations with experts and key opinion leaders in overseas markets, positioning itself as an emerging player in the global structural heart interventions space.
Average Trading Volume: 362,184
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.52B
See more data about 9877 stock on TipRanks’ Stock Analysis page.